Delivery Order SPE2DB25D3017-SPE2DB25FVKER
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $5,144.31. This is a firm fixed-price delivery order with an ultimate completion date of August 28, 2025, and represents a non-set-aside, competitively awarded procurement. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $13,994.32 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on August 25, 2025, with ultimate completion by August 26, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a ceiling value of $1,525.20. This firm fixed-price delivery order is scheduled for completion by August 1, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a non-set-aside competitive procurement under the company's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections valued at $13,477.84. This firm fixed-price delivery order, which represents a child contract under a larger indefinite delivery vehicle, will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, with an ultimate completion date of September 9, 2025. The award was made on a competitive basis with no...
- The Defense Logistics Agency awarded a delivery order valued at $2,819.81 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen (semaglutide injection) on August 25, 2025, with completion scheduled for August 26, 2025. This is a firm fixed price, non-set-aside contract with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a ceiling value of $1,906.45. The award, made on August 8, 2025, is a firm fixed-price delivery order with an ultimate completion date of August 11, 2025. This non-competitive set-aside contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete...
- The Defense Logistics Agency awarded a $35,751.17 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $8,787.92 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pens on May 12, 2025, with completion expected by May 13, 2025. This firm fixed-price delivery order represents a non-competitive award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion pharmaceutical prime vendor vehicle running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $16,675.15 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens on July 31, 2025, with completion scheduled for August 1, 2025. This firm fixed-price contract, which was not set-aside, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves...
- The Defense Logistics Agency awarded a $5,231.11 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injectors. This competitively awarded, firm fixed price delivery order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the vendor's demonstrated capability to compete in...
- SPE2DB25D3017Indefinite Delivery Contract
- SPE2DB25D3017-SPE2DB25FVKERDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $20,839.40 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on August 12, 2025, with completion scheduled for August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and a key distribution hub for federal pharmaceutical procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor for the Defense Logistics Agency's Medical Supply Chain, AmerisourceBergen supplies an extensive portfolio of medications and medical products to support military and veteran healthcare systems. The DLA Troop Support Medical procurement vehicle enables the company to distribute critical pharmaceuticals, including specialty medications and biologics, to federal healthcare beneficiaries including the Defense Health Agency and U.S. Coast Guard. Zepbound is a GLP-1 receptor agonist indicated for weight management in eligible patients and represents part of the company's comprehensive pharmaceutical distribution capability within the federal supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.8k | 8/12/25 |